

SR Pharma plc

Grant of Options

London 27 November 2006 – SR Pharma plc (the Company) announces the grant on Friday 24 November of options over SR Pharma Ordinary Shares of 1p each under the Company's unapproved share option scheme to directors and staff as follows:

	Number of options	Exercise price	Earliest exercise date	Latest exercise date
Iain Ross	400,000	43p	Immediate	24 November 2016
Melvyn Davies	200,000	43p	Immediate	24 November 2016

In addition, 600,000 options have been granted on the same terms to management of SR Pharma's subsidiary, Atugen AG.

The exercise price is the market price at close of business on Friday 24 November.

- Ends -

SR Pharma (www.srpharma.com)

SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG (www.atugen.com) based in Berlin, Germany and Stanford Rook Ltd based in London, UK.

Atugen is a leader in RNAi therapeutics. This Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietary delivery system ("AtuPLEX") both of which have advantages over conventional siRNA molecules and their delivery systems. Currently Atugen and its collaboration partners have lead molecules in pre-clinical development for a variety of therapeutic indications. Clinical development of AtuRNAi therapeutic molecules for systemic applications in Atugen's oncology programs are targeted to start in 2007. Other clinical AtuRNAi therapeutic programs of Atugen's collaborators are scheduled to commence in 2H 2006.

Stanford Rook Ltd owns a proprietary Mycobacterium vaccae-based technology and related products, and a number of other proprietary immunotherapeutic compounds and related intellectual property. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of M. vaccae and related products.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements.

Enquiries:

For further information, please contact the following:

SR Pharma plc

+44(0)20 7307 1620

Iain Ross, Chairman

Melvyn Davies, Finance Director

Atugen AG

+49(0)30 9489 2800

Thomas Christély, Chief Executive Officer

Dr. Klaus Giese, Chief Scientific Officer

Northbank Communication

+44(0)20 7886 8150

Sue Charles, Justine Lamond

srpharma@northbankcommunications.com